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Summary Inactivation of the tumour-suppressor gene p53 has been demonstrated in a variety of human
tumours. We extracted DNA from paraffin-embedded tissues of 67 ovarian carcinoma samples (54 primary
tumours, seven metastases and six tumours obtained after chemotherapy), and analysed allelic losses and
mutations of the p53 gene using single-strand conformation polymorphism (SSCP) analysis of DNA fragments
amplified by a polymerase chain reaction (PCR). Allelic loss was observed in 24 of 32 informative cases. The
mutation was detected in 14 of 54 primary ovarian carcinomas: eight serous cystadenocarcinomas (SCA,
42%), five endometrioid adenocarcinomas (EA, 42%) and one mucinous cystadenocarcinoma (14%). The
incidence of the alteration was higher in SCA and EA than in other histological types, but the difference was
not statistically significant. The incidence of p53 gene abnormalities in ovarian carcinomas tended to be
increased in patients with disease advanced (over FIGO stage II). Mutations were found in exons 5 and 7 only
and consisted mainly of single nucleotide substitutions [9 of 14 (64%) in exon 7; 4 of 14 (29%) in exon 5]. In
13 of 14 cases, p53 gene mutations occurred concomitantly with losses of the normal allele. The status of the
p53 gene in metastases and the tumours obtained after chemotherapy was identical to that in the primary
tumours. The presence of p53 gene mutation did not correlate with histological grade, response to primary
therapy and survival. These findings suggest that mutational alterations of the p53 gene are involved in the
development of a significant proportion of some ovarian carcinomas (SCAs or EAs), especially in advanced
stages. However, they may not be a marker predicting the biological behaviour or the outcome of the disease.
The p53 gene which encodes a nuclear phosphoprotein of
53 kDa, appears to be a frequent target for genetic abnor-
malities in a large number of human tumours. The p53 gene
lies on chromosomal locus 17pl3.1 (Umesh et al., 1988),
where one allele is frequently deleted, and mutation often
occurs on the remaining allele. These alterations of the p53
gene have been found in many human cancers, such as those
of the colon (Baker et al., 1990; Rodriguez et al., 1990), lung
(Takahashi et al., 1989; Chiba et al., 1990), breast (Prosser et
al., 1990; Bartek et al., 1990), liver (Fujimori et al., 1991;
Slagle et al., 1991) and brain (Nigro et al., 1989). Wild-type
p53 product can suppress transformation in vitro, whereas
mutated p53 protein may inactivate the wild-type p53 func-
tion, resulting in cell transformation (Finlay et al., 1989;
Eliyahu et al., 1989; Baker et al., 1990). These findings are
consistent with the concept that the wild-type p53 gene prod-
uct functions as a suppressor of neoplastic growth.
Although ovarian cancer is the leading cause of death
among all carcinomas of the female reproductive tract, the
genetic alterations involved in ovarian carcinoma remain
largely unknown. As is the case with other common human
carcinomas (Hunter, 1991), accumulation of multiple genetic
alterations must be present in ovarian carcinoma, playing
significant roles in carcinogenesis and tumour progression.
Amplification of the HER-21/neu (Slamon et al., 1989), c-
myc (Zhou et al., 1988) and c-K-ras (Filmus & Buick, 1985)
genes has been detected in ovarian carcinoma, however the
incidence of such amplifications is not high. On the other
hand, some data are available on the alterations of p53 gene
in ovarian carcinoma (Eccles et al., 1990, 1992; Lee, 1990;
Marks et al., 1991; Mazars et al., 1991; Okamoto et al.,
1991), but little information is available regarding the prog-
nostic significance of the p53 gene abnormalities.
The present study was undertaken to examine alterations
of the p53 gene in a series of 54 ovarian carcinomas using
PCR-SSCP' analysis (Orita et al., 1989; Hayashi, 1991). The
utilisation of DNA samples extracted from paraffin-
embedded tissues prompted us to investigate retrospectively
allelic losses and mutations of the p53 gene and their associa-
tion with clinicopathological findings. A chemiluminescent
detection system (Beck et al., 1989; Creasey et al., 1991) was
adapted for PCR-SSCP analysis in order to eliminate the
hazards and long exposure times associated with the original
radioactive method. We examined p53 gene mutation not
only in exons 5-8, where most of the evolutionarily con-
served amino acids are concentrated (Hollstein et al., 1991),
but also in exon 4, where some mutations have been reported
in ovarian cancer (Okamoto et al., 1991). We also detected
allelic losses of p53 gene from a polymorphism in exon 4
(Buchman et al., 1988) represented by PCR-SSCP analysis
(Orita et al., 1989; Okamoto et al., 1991).
Materials and methods
Patients
Fifty-seven patients with ovarian carcinoma were employed
in this study. Each patient underwent exploratory
laparotomy as part of treatment for ovarian carcinoma at the
Gifu University Hospital between 1984 and 1991. Verbal
consent to the use of samples for analysis was obtained from
patients after full explanation of the nature of the studies to
be carried out. Fourteen patients with benign ovarian cyst
(seven serous cystadenomas, four mucinous cystadenomas
and three dermoid cysts) and three ovaries showing
pathologically no abnormalities (as an internal control of
constitutional genotype) were also examined. Histological
type and grade of the tumours were assigned according to
the WHO criteria (Serov & Scully, 1973). The clinical stage
was evaluated according to the typing system of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO,
1982). In 3 of the 57 ovarian cancers, PCR-SSCP analyses
were unsuccessful because of the poor quality of the DNA
extracted. Among the remaining 54 ovarian carcinomas with
available data on p53 gene alteration, 51 were of epithelial
origin: 19 serous cystadenocarcinomas, 12 clear cell car-
cinomas, 12 endometrioid adenocarcinomas, seven mucinous
cystadenocarcinomas and one undifferentiated carcinoma.
The other three were squamous cell carcinomas arising from
mature cystic teratoma. The histological grades of those 54
ovarian cancers were: well differentiated in 14 cases,
moderately differentiated in 19 cases and poorly
differentiated in 21 cases. There were 15 cases in stage I, 11
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in stage II, 20 in stage III and eight in stage IV. None of the
54 patients with ovarian carcinomas had received any
chemotherapy or radiotherapy prior to the surgery. All of
them had received cisplatin/doxorubicin/cyclophosphamide
chemotherapy following primary surgical exploration.
PCR-SSCP analysis
All of the DNA samples were extracted from tumour tissues
embedded in paraffin blocks. Areas of tumours containing a
large proportion ofneoplastic cells (approximately over 90%)
were identified histopathologically in tissue sections. The
serial 20-30 tissue sections (20gm thick) with abundant
tumour cells were deparaffined in xylene and incubated for
48-96 h at 37°C in lysis buffer containing 0.1 mg ml-' pro-
teinase K (Jackson et al., 1991). After complete digestion,
DNA was purified by deproteination with saturated sodium
chloride (Miller et al., 1988) and precipitation by ethanol.
The concentration of DNA was spectrophotometrically deter-
mined, and the DNA solution at a concentration of
100 ngml' was used as a template for the following PCR
procedure.
To amplify coding exons 4-8 of the p53 gene, the follow-
ing oligonucleotide primers were designed using published
sequence data (Buchman et al., 1988) and synthesized by the
phosphoramidite method: E4U, 5'-TTCACCCATCTACAG-
TCC-3'; E4D, 5'-CTCAGGGCAACTGACCGT-3'; E5U, 5'-
TTCCTCTTCCTGCAGTACTCC-3'; E5D, 5'-GCCCCAG-
CTGCTCACCATCGC-3'; E6U, 5'-CACTGATTGCTCTT-
AGGTC-3'; E6D, 5'-AGTTGCAAACCAGACCTCA-3';
E7U, 5'-TCCTAGGTTGGCTCTGAC-3'; E7D, 5'-CAAGT-
GGCTCCTGACCTG-3';E8U, 5'-CCTATCCTGAGTAGT-
GGTAA-3'; E8D, 5'-CCTGCTTGCTTACCTCGCT-3'. For
instance, E4U and E4D are upstream (sense) and down-
stream (antisense) primers, respectively, covering exon 4, the
expected sizes of PCR fragments are 309 bp (exon 4), 214 bp
(exon 5), 141 bp (exon 6), 131 bp (exon 7) and 162 bp (exon
8). For chemiluminescent detection of SSCP, all of the
primers were biotinylated at the 5' terminus with the Biotin-
ON phosphoramidite (Clontech, Palo Alto, CA, USA). The
PCR mixture in a total volume of 20 Al contained 100 ng of
genomic DNA, 0.2 mM each of dNTPs, 0.25 mM each of
biotinylated primers, 1.5 mM magnesium chloride, 50 mM
potassium chloride, 10 mM Tris-HCI, pH 8.3, 0.01% gelatin
and 0.5 units of Taq DNA polymerase. Thirty cycles consis-
ting of 20 s at 94°C, 20 s at 55°C and 30 s at 72°C were
performed.
For SSCP analysis, a 2pi aliquot of the PCR product was
diluted 50-fold with a loading solution containing 20 mM
EDTA, pH 8.0, 95% formamide, 0.05% bromophenol blue
and 0.05% xylene cyanol. The diluted samples were heated at
90°C for 5 min, and 2 gd of the samples were applied to two
non-denaturing polyacrylamide gels (0.5 x HydroLink MDE
gel; AT Biochem, Malvern, PA, USA), one containing 5%
glycerol and the other without glycerol. Electrophoresis in
the gels with and without glycerol was performed at a con-
stant power of 6 W for 12 h and 6 h respectively, at room
temperature. Then, the DNA fragments in the gels were
transferred to a nylon membrane (Immobilon-S; Millipore,
Bedford, MA, USA) by capillary blotting for 30 min using
0.5 x Tris-borate buffer without any pretreatment of the gels.
By this procedure, about a third of the DNA fragments was
transferred to the membrane surface. The gels containing
untransferred DNA fragments were stored at 370C in
humidified air until cutting of the gel pieces containing a
mobility-shift band. After transfer, the membrane was dried.
and the DNA fragments were cross-linked to the membrane
by ultraviolet irradiation (33,000 mJ cm2 at 254 nm). The
bands ofbiotin-labelled DNA fragments were detected with a
Plex 5 Chemiluminescent Subkit (New England BioLabs,
Beverly, MA, USA) basically according to the report of
Creasey et al. (1991). The luminescing band patterns were
recorded on standard X-ray film with an exposure time of
15-30 min. In the SSCP analysis for exon 4, the signal
intensity of the bands was determined by a Bio Image 505
System (Millipore).
Sequencing analysis
By laying the developed film of SSCP analysis on the stored
gel, an area of the gel containing a mobility-shift band was
determined and cut out. DNA fragments were eluted from
excised gel slices by the crush and soak method (Sambrook et
al., 1989), and were amplified by a PCR under the same
conditions as described above. The sequences of the primers
used were identical to those used in the prior PCR but were
not biotinylated. The PCR products were fractionated by
electrophoresis through 12% non-denaturing polyacrylamide
gels. The DNA fragments with an expected size were eluted
from excised gel slices, and ligated to pT7 Blue T-vector
(Novagen, Madison, WI, USA). After transformation of
Nova Blue competent cells (Novagen), double-strand plasmid
DNA was isolated, and both sense and antisense strands
were sequenced by using a Circum Vent thermal cycle
dideoxy DNA sequencing kit (New England BioLabs) with
biotinylated M13/pUC reverse sequencing primer and
biotinylated T7 promoter primer. Sequencing products were
electrophoresed on denaturing polyacrylamide gels (5%
HydroLink Long Ranger gel; AT Biochem) at a constant
power of 75 W for 3 h. The procedure for chemiluminescent
detection of DNA band patterns was identical to that in
SSCP analysis. Sequence analysis was carried out on several
clones from independent PCR products to eliminate sequenc-
ing errors due to polymerase misincorporations. In addition,
it was confirmed that the PCR fragment generated from the
cloned DNA using the same set of primers migrated to the
same position as the abnormal fragment generated from the
respective cellular DNAs.
Statistics
Statistical analyses were done using Fisher's exact probability
test or Student's t-test. Survival estimates were calculated
using the product limit method of Kaplan and Meier (1956).
Differences in survival were tested using the log-rank statistic
(Mantel, 1966).
Results
Allelic losses ofp53 gene
Since there is sequence polymorphism at codon 72 in exon 4
(Buchman et al., 1988), the DNA fragment covering exon 4
was amplified by a PCR, and analysed by the SSCP method.
Depending on the presence or absence of 5% glycerol in the
gel, the mobilities and the separation patterns of allelic bands
varied but they were evident and reproducible under each
condition. Figure I shows the representative results of SSCP
analysis of the gel without glycerol. Polymorphism at codon
72 in exon 4 was represented by three bands with different
mobility. Sequence analysis revealed that the band on the top
(band 1, B1) and the band in the middle (band 2, B2)
contained the arginine codon (CGC) and the proline codon
(CCC), respectively, and that the band at the bottom corres-
ponded to each of the complementary strands which co-
migrated under these conditions. Allelic loss was able to be
detected by PCR-SSCP analysis without corresponding nor-
mal tissues, because a residual weak signal, presumably
derived from normal cells in the tumour specimen, was
observed in most of the tumours with a - heterozygous
genotype (for example cases 2, 3, 4, 7 and 8 in Figure 1).
According to the criteria ofOkamoto et al. (1991), allelic loss
is considered to have occurred if tumours show a
heterozygous genotype and the signal intensity of a paired
allelic fragment is less than 40% of the other paired
fragments.
Signal intensity of one of the bands BI and B2 was
reduced in 18 of the 26 ovarian carcinomas with aGENE ALTERATION IN OVARIAN CARCINOMA 1193
heterozygous genotype, indicating the presence of allelic loss
(for example cases 2, 3, 4 and 8 in Figure 1). Moreover, in
six cases with a homozygous genotype and p53 gene muta-
tion (cases 1, 5, 6, 9, 12 and 14 in Figure 1 and Table I),
allelic loss was confirmed by a reduced intensity of the
corresponding normal bands as described below. The 32
cases of the 54 ovarian carcinomas examined were infor-
mative, and allelic loss was detected in any of the seven
informative cases with benign ovarian cyst (walls of three
serous cystadenomas, two mucinous cystadenomas and two
dermoid cysts).
Mutations ofp53 gene
Since allelic loss of p53 gene was frequently observed in
ovarian carcinomas, we further examined for mutations of
N 1 2 3 4 5 6 7 8
B2
Figure 1 SSCP analysis of PCR fragments of exon 4 of the p53
gene. Electrophoresis was performed using non-denaturing
polyacrylamide gel without glycerol at room temperature.
Numbers on the top of each lane correspond to case numbers
shown in Table 1. Lane N was loaded with PCR fragments
generated from normal human placental DNA. The bands Bi
and B2 correspond to the allele carrying CGC and that carrying
CCC, respectively, at codon 72. Cases 1, 5 and 6 were found to
be constitutionally homozygous. The ratio of signal intensity of
bands B1 and B2 (a weaker signal to the other one) was: lane N,
0.881; lane 2, 0.273; lane 3, 0.182; lane 4, 0.235; lane 7, 0.702; and
lane 8, 0.342.
the gene by PCR-SSCP analysis. The five DNA segments
covering exons 4, 5, 6, 7 and 8 were amplified by a PCR and
analysed by the SSCP method. Figure 2 shows the represen-
tative results of SSCP analysis of the gel without glycerol.
The PCR fragments of normal placental DNA exhibited two
bands for exons 6 and 8, representing the two complemen-
tary single strands of DNA. On the other hand, in the cases
of exons 5 and 7, the two slower moving bands (BI and B2)
and the two faster moving bands (B3 and B4) were observed
for normal placental DNA. The DNAs in bands B1 and B2
were confirmed to have exactly the same nucleotide sequence,
suggesting that the strands having the same sequence can
have two stable conformations. The DNAs in bands B3 and
B4 also had the same nucleotide sequence. These results
indicate that the single-stranded DNA in bands BI and B2 is
complementary to that in bands B3 and B4.
In the SSCP analysis of the gel without glycerol, 14
ovarian carcinomas showed the bands with different mobility
in one of the three PCR fragments (exons 5, 6 and 7 in
Figure 2), whereas none of the walls of 14 benign ovarian
cysts and three normal ovaries examined showed any band
with different mobility. SSCP analysis of the gel containing
5% glycerol yielded the same result, although the pattern of
separations of the bands was varied. When a normal allele is
retained in the tumour, the intensity of bands for mutated
allele should be the same as or less than that of bands for
normal allele. In cases 1, 2, 4, 5, 6, 8, 9, 10, 11, 12 and 14 in
Figure 2, the intensity of bands with different mobility was
higher than that of the corresponding normal bands,
indicating the presence of loss of normal allele. However, in
cases 3, 7 and 13 in Figure 2, we were not able to detect any
loss of normal allele, because the intensity of the band with
different mobility was lower than that of the bands for
normal allele.
In the 14 DNA samples showing bands with different
mobility, sequence analyses were performed to confirm the
presence of mutated p53 genes and to determine the type of
mutations (Figure 3). As summarised in Table I, sites of
mutations were distributed between codons 143 and 249,
mutations tended to cluster in exons 5 and 7 [9 of 14 in exon
7 (64%); 4 in exon 5 (29%); and I in exon 6 (7%)]; 11 (79%)
of 14 mutations were detected on the highly conserved
regions (Hollstein et al., 1991), and the other three mutations
were found at codons corresponding to amino acids con-
served among several species (Hollstein et al., 1991). Thirteen
of the 14 cases with mutation had concomitant loss of the
normal allele. Twelve mutations revealed single nucleotide
substitutions (missense mutations), ten of which were transi-
tions (from G:C to A:T in eight cases and from A:T to G:C
in one case), and the other two were transversions from G to
T. Cases 4 and 6 revealed a three-base deletion, resulting in
the deletion of codons 218 (valine) and 234 (tyrosine) respec-
Table I Alteration of the p53 gene and correlation of allelic loss in ovarian carcinomas
Mutation
Histology Allelic Nucleotide Amino acid FIGO
Case Tjpea Gradeb lossc Exon Codon change change stage
I SCA W +, CH, LON 5 181d CGC to CACe Arg to His I
2 SCA P +, LOB2, LON 7 245d GGC to AGC Gly to Ser II
3. SCA P +, LOBI 7 248d CGG to CAG' Arg to Gin III
4 SCA M +, LOB2, LON 6 218 GTG deleted Val deleted III
5 SCA P +, CH, LON 7 245d GGC to GTC Gly to Val III
6 SCA M +, CH, LON 7 234d TAC deleted Tyr deleted IV
7 SCA P -,ROH 7 249d AGG to AGT Arg to Ser IV
8 SCA P +, LOBI, LON 7 249d AGG to AGT Arg to Ser IV
9 EA W +, CH, LON 5 175d CGC to CACe Arg to His III
10 EA M +, LOB2, LON 7 245d GGC to AGC Gly to Ser III
II EA M +, LOBI, LON 5 163 TAC to TGC Tyr to Cys III
12 EA M +, CH, LON 7 241d TCC to TTC Ser to Phe III
13 EA M +, LOB2 5 143 GTG to ATG Val to Met IV
14 MCA W +, CH, LON 7 248d CGG to TGG' Arg to Trp I
'SCA, serous cystadenocarcinoma; EA, endometrioid adenocarcinoma; MCA, mucinous cystadenocarcinoma. bW,
well differentiated; M, moderately differentiated; P, poorly differentiated. CGH, constitutional homozygosity; LOBI,
loss of band Bl; LOB2, loss of band B2; ROH, retention of heterozygosity; LON, loss of normal allele. dCodons
within evolutionary conserved regions of the p53 gene. 'Transitions at a CpG dinucleotide.1194 K. NIWA et al.
tively. Transitions at a CpG dinucleotide were detected in
four of the 14 mutations.
Clinicopathologicalfeatures andprognosis ofovarian
carcinomas showingp53 gene alteration
The heterogeneity of ovarian carcinomas examined with
respect to the presence of p53 gene alterations prompted us
to analyse possible correlations with clinicopathological char-
acteristics of ovarian carcinomas. As summarised in Table II,
there was no significant relationship between p53 gene altera-
tions and age at diagnosis, clinical stage or histological grade.
The rate of p53 gene abnormalities in ovarian carcinomas
tended to be increased in advanced stage (over FIGO stage
Exon 5 Exon 6 Exon 8
II). However, no significant relationship was also found
between allelic loss and histological type.
On the other hand, mutations were frequent in serous
cystadenocarcinoma (42%) and endometrioid adenocar-
cinoma (42%) but infrequent in mucinous cystadenocar-
cinoma (14%). The nucleotide changes in serous cys-
tadenocarcinoma did not show any specific pattern: three
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Figure 2 Detection of p53 gene mutations by SSCP analysis.
Electrophoresis was performed using non-denaturing polyac-
rylamide gel without glycerol at room temperature. Numbers on
the top of each lane correspond to case numbers shown in Table
I. Lane N was loaded with PCR fragments generated from
normal human placental DNA. Normal alleles were indicated by
the bands B1, B2, B3 and B4 in exons 5 and 7, and by
arrowheads in exons 6 and 8. Abnormal shifted bands were
detected in cases 1-14.
Figure 3 Sequencing analysis of p53 gene mutations. Case
numbers correspond to those shown in Table I. Upper right: A
point mutation at codon 245 (exon 7) from GGC to AGC.
Middle right: A deletion of three bases (TAC) at codon 234 (exon
7). Lower right: a point mutation at codon 163 (exon 5) from
TAC to TGC. The arrows indicate the positions of mutations or
deletions. The wild-type sequences are shown on the left.
Table II Correlation between p53 gene alteration and clinicopathological parameters in
ovarian carcinoma
Allelic losSa Mutationb
Positive Negative Positive Negative
Median age at diagnosis 55.0 50.5 49.5 51.0
FIGO stage
1 5 (56%)C 4 (44%) 2 (13%) 13 (87%)
II 6 (86%) 1 (14%) 1 (9%) 10 (91%)
III 10 (83%) 2 (17%) 7 (35%) 13 (65%)
IV 3 (75%) 1 (25%) 4 (50%) 4 (50%)
II-IV 19 (83%) 4 (17%) 12 (31%) 27 (69%)
Histological grade
Well differeniated 4 (57%) 3 (43%) 3 (21%) 11 (79%)
Moderately differentiated 8 (62%) 5 (38%) 7 (37%) 12 (63%)
Poorly differentiated 10 (83%) 2 (17%) 4 (19%) 17 (81%)
Histological typec
SCA 9 (82%) 2 (18%) 8 (42%)C 11 (58%)
CCC 4 (67%) 2 (33%) 0 (0%) 12 (100%)
EA 6 (75%) 2 (25%) 5 (42%)- 7 (58%)
MCA 2 (50%) 2 (50%) 1 (14%) 7 (86%)
SCC 2 (100%) 0 (0%) 0 (0%) 3 (100%)
UC I (100%) 0 (0%) 0 (0%) 1 (100%)
a32 patients with available data on allelic loss of p53 gene. b54 patients with available
data on mutation of p53 gene. cNumber of patients (%). dSCA, serous
cystadenocarcinoma; CCC, clear cell carcinoma; EA, endometrioid adenocarcinoma;
MCA, mucinous cystadenocarcinoma; SCC, squamous cell carcinoma; UC,
undifferentiated carcinoma. eSignificantly higher than the group of clear cell carcinoma
(P<0.05).
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Table III Relation between p53 gene alteration and clinical
parameters in ovarian serous tumours and endometroid
adenocarcinoma
Number of cases Number of cases in
examined pS3 mutation 'positive'
Pathology
Serous tumours
Serous cystadenoma
Serous cystadenocarcinoma
Well differentiated
Moderately differentiated
Poorly differentiated
FIGO stage
I
II
III
IV
II-IV
Endometrioid adenocarcinoma
Well differentiated
Moderately differentiated
Poorly differentiated
FIGO stage
I
II
III
IV
II to IV
7
3
6
10
3
2
9
5
16
1.0
0.8
a)
1>1
n
Y)
0 (0%)
1 (33%)
2 (33%)
5 (50%)
0.6
0.4
0.2
U.u
3
3
7
6
6
0
(33%)
(50%)
(33%)
(60%)
(44%)
1 (17%)
4 (67%)
0
2
2
6
2
10
0
0
4
5
(0%)
(0%)
(67%)
(50%)
(50%)
cases ofG:C to A:T transition, two cases of G to T transver-
sion, two cases of three-base deletion and one case of A:T to
G:C transition. On the other hand, G:C to A:T transitions
were the most frequent substitution (4/5 cases) in endomet-
rioid adenocarcinoma. No mutation was found in 12 clear
cell carcinomas, three squamous cell carcinomas and one
undifferentiated carcinoma.
We were able to evaluate p53 gene alteration in both the
primary tumour and 1-3 metastases in three patients with
allelic loss and mutation (cases 3, 8 and 12) and four patients
with allelic loss but without mutation, in whom the tumour
was obtained at the initial cytoreductive surgery. In all seven
patients, the genetic alteration revealed in the metastases was
identical to that in the primary tumour. We were also able to
compare the status of the p53 gene before and after
chemotherapy in three patients with allelic loss and mutation
(cases 5, 7 and 12) and in three patients with allelic loss but
without mutation, in whom the tumour was obtained at the
second-look or subsequent laparotomy. The status of the p53
gene did not change during the course of post-operative
chemotherapy in any of the six patients.
In Table III, the relation between p53 alteration and either
histological grade or FIGO stage in serous tumours and
endometrioid adenocarcinomas is shown. In ovarian serous
tumours, allelic loss or the mutation of p53 gene was not
detected in benign serous adenomas, whereas the incidence of
mutation in serous cystadenocarcinoma was relatively high
(8/19, 43%) and the incidence of the mutation seemed to be
higher in accordance with de-differentiation. The incidence in
FIGO III/IV seemed to be slightly higher than that in FIGO
I/TI. In endometrioid adenocarcinoma, the incidence in
moderately differentiated cases seemed to be higher than in
well-differentiated cases. According to the FIGO stage, the
incidence ofp53 mutation in FIGO stage III/IV seemed to be
higher than that in FIGO stage I/II.
One (8%) of the 12 evaluable patients with p53 gene
mutation (six with progressive disease and six second looks)
and four (17%) of the 24 evaluable patients without p53 gene
mutation (nine with progressive disease and 15 second looks)
revealed a negative second look; no relationship was found
between the presence of p53 gene mutation and the incidence
of surgically documented complete response (P>0.4).
Among the five patients who had a negative second-look
laparotomy, one patient without p53 gene mutation has
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Figure 4 Relationship between p53 gene mutation and survival
in 31 patients with ovarian cancer. , survival curve in 13
patients with p53 gene mutation; ----, survival curve in 18 patients
without p53 gene mutation. The tick marks represent the follow-
up times of living patients.
subsequently showed recurrence of the disease. The other
three patients are alive with no evidence of the disease. Since
most of the p53 gene mutations confirmed in this study were
observed in serous cystadenocarcinoma and endometrioid
adenocarcinoma (Table I), we examined the relation between
p53 gene mutation and survival time in 31 patients (19
patients with serous cystadenocarcinoma and 12 patients
with endometrioid adenocarcinoma) (Figure 4). Although the
median survival time of the 13 patients with p53 gene muta-
tion (20.1 months) was somewhat worse than that of the 18
patients without p53 gene mutation (28.2 months), the
difference normalised by clinical stage was not statistically
significant (P>0.5).
Discussion
Several reports (Okamoto et al., 1991; Mashiyama et al.,
1991; Tamura et al., 1991; D'Amico et al., 1992) have
documented the effectiveness of PCR-SSCP analysis for
detecting mutations of p53 gene. In this study we extracted
DNA from paraffin-embedded tissues because PCR does not
require high molecular weight DNA as a template. This
approach makes possible retrospective analysis of tissue spec-
imens several years old (Jackson et al., 1991), although the
length of DNA fragments that can be amplified by PCR
depends on the integrity of the template DNA. Shorter DNA
fragments are better suited for detection of mutations by
SSCP analysis; the sensitivity of SSCP analysis is more than
99% for DNA fragments of 100-300bp (Hayashi, 1991).
When the DNA fragments analysed by SSCP are less than
approximately 300 bp, the possibility of a false-negative
result is quite low under two conditions (Hayashi, 1991;
Hayashi & Yandel, 1993). The SSCP electrophoresis was
performed in the gels with and without 5% glycerol in the
present study. For these reasons, we performed PCRs on
each of exons 4-8 of the p53 gene, resulting in successful
SSCP analyses on most of the DNA samples extracted from
paraffin-embedded tissues.
Using PCR-SSCP analysis, we detected allelic losses of
the p53 gene in 24 (75%) of the 32 informative ovarian
cancers, whereas, as expected, allelic loss was not detected in
any of the seven benign ovarian cysts with heterozygous
genotypes. The frequency ofallelic loss in the ovarian cancers
examined in this study was similar to that in the previous
reports (Eccles et al., 1990; Lee et al., 1990; Okamoto et al.,
1991) on loss of heterozygosity of chromosome 17 detected
by restriction fragment length polymorphism analysis. We
also found 14 cases with p53 gene mutation (26%) in 54
ovarian cancers. This frequency of mutation was lower than
that of allelic loss, and not as high as those for carcinomas of
the colon (Baker et al., 1990; Rodriguez et al., 1990) and
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lung (Takahashi et al., 1989; Chiba et al., 1990). We regard
our value as a conservative estimate for the following
reasons. All primers were designed such that they included
several of the first or last nucleotides of exons (Buchman et
al., 1988). Therefore, mutations occurring in the regions
included in the primers, such as splice site mutation, could
not be detected. It is also possible that mutations might be
present in a region of p53 gene that was not targeted in the
present study. Furthermore, there may be undetectable muta-
tions by SSCP analysis, because the strands with different
sequences sometimes have the same stable conformation and
co-migrate, as in the case of exon 4 (Figure 1). We also
cannot rule out the possibility that genetic mutations are
masked by a high proportion of non-cancerous cells con-
tained in tumour specimens.
Sequence analysis revealed 12 single point mutations and
two deletions. Nine cases had not only p53 gene mutations in
the highly conserved regions of p53 gene, but also allelic
losses of p53 gene, strongly suggesting the complete loss of
normal p53 function. Most of the p53 gene mutations
confirmed in this study were observed in serous cys-
tadenocarcinoma and endometrioid adenocarcinoma. In
serous tumours, no alterations of p53 gene could be detected
in benign serous cystadenomas. From the point of view of
relationship between differentiation and p53 alteration in
serous tumours, the incidence of the alteration seemed to be
increased in accordance with de-differentiation. In endomet-
rioid adenocarcinoma, a similar tendency was also found.
The nucleotide changes were not confined to a specific pat-
tern in serous cystadenocarcinoma. In contrast, G:C to A:T
transitions constitute the majority of mutations in endomet-
rioid adenocarinoma. The pattern of mutations seen in the
present study is similar to that reported for other epithelial
tumours, and the frequency of the G:C to A:T transversion
in ovarian endometrioid adenocarcinoma is considered to
resemble to that in hepatocellular carcinomas (Caron de
Fromentel & Soussi, 1992). No mutation was detected in 12
clear cell carcinomas, in agreement with the result of
Okamoto et al. (1991). It is probable that the disparity
between these mutational spectra is due to differences in
metabolic and DNA repair capacities among different cell
types (Harris, 1989). One of the features of the p53 muta-
tional spectra in human cancers is that transitions at CpG
dinucleotides contribute heavily to the mutational frequency
in many cancers (Hollstein et al., 1991). In the present series
of ovarian cancer, transitions at CpG sites were found in
four (29%) of 14 mutations, and this frequency was relatively
low compared with that of colon cancer (67%) (27).
Methylation of CpG sites and the level of spontaneous
deamination may differ in various tissue types.
Eccles et al. (1992) reported the relation between
immunohistochemical overexpression ofp53 protein in frozen
sections and allele loss at 17p in ovarian carcinoma. Their
hypothesis using immunohistochemistry could be confirmed
by the SSCP and direct sequencing in the present study. In
particular, in ovarian serous tumorigenesis in the present
study, allelic loss or mutation of p53 gene was not detected
in benign serous adenoma, whereas the incidence of altera-
tion in serous cystadenocarcinoma was relatively high (43%)
and the incidence of the alteration seemed to be higher in
accordance with de-differentiation. Recent work on colorectal
tumours (Baker et al., 1990b) suggested that alteration of the
p53 gene might be the rate-limiting step in tumorigenesis.
Thus, in ovarian serous tumorigenesis, the point mutation in
the p53 gene might be the rate-limiting step and the loss of
the remaining wild-type allele might occur afterwards as a
tumour changes from benign to malignant.
In this study, we determined whether p53 gene mutation
correlated with prognostic factors in ovarian cancer. As a
result, no correlation was revealed between p53 gene muta-
tion and histological grade, which has been used with some
success for predicting the eventual clinical outcome (Ozols et
al., 1992). We also found no relationship between p53 gene
mutation and response to primary therapy. No correlation
was found between p53 gene mutation and survival time in
the 31 patients with serous cystadenocarcinoma or endomet-
rioid adenocarcinoma, with or without cases with the muta-
tions identified.
The present study suggests that alterations of the p53 gene
might be involved in the development of a proportion of
ovarian carcinomas, especially in serous tumorigenesis, and
might play an important role in commencement of invasion.
However, they could not have an important role as a
mechanism for aggressive biological behaviour of the disease.
Further investigations will be required to elucidate the multi-
ple genes, oncogenes and tumour-suppressor genes involved
in the ovarian carcinogenesis and to understand their
biological and clinical significance.
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